Skip to main content

Table 3 Estimation of tumor content by segmentation in the CRL-2324 dilution series (data set 3)

From: Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays

  Hemizygous loss 18q21.32-q22.3 Single copy gain 13q11-q12.3 CNN LOH 13q21.31-qter§
Tumor (%)* Expected mBAF Observed mBAF Tumor (%) Expected mBAF Observed mBAF Tumor (%) Expected mBAF Observed mBAF Tumor (%)
0 0.5 0.53 12 0.5 0.53 15 0.5 0.53 6
10 (7-12) 0.53 0.53 11 0.52 0.53 12 0.55 0.54 7
14 (10-17) 0.54 0.53 12 0.53 0.53 12 0.57 0.55 9
21 (17-26) 0.56 0.55 18 0.55 0.54 16 0.6 0.58 16
23 (18-28) 0.56 0.6 32 0.55 0.56 28 0.62 0.64 28
30 (24-35) 0.59 0.58 27 0.57 0.55 21 0.65 0.62 24
34 (28-40) 0.60 0.59 31 0.57 0.55 23 0.67 0.64 29
45 (38-51) 0.65 0.61 37 0.59 0.56 27 0.72 0.67 33
47 (40-54) 0.65 0.65 46 0.6 0.57 35 0.74 0.71 42
50 (43-57) 0.67 0.64 43 0.6 0.57 30 0.75 0.7 39
79 (74-83) 0.83 0.84 81 0.64 0.6 51 0.9 0.89 77
100 1 0.93 93 0.67 0.65 88 1 0.95 89
  1. *95% confidence interval within parentheses. Hemizygous loss chr18:54400001-71300000. Single copy gain chr13:16000001-31100000. §Copy number neutral LOH chr13:60500001-114142980.